Active Clinical Trials | Saint John’s Cancer Institute

What is a clinical trial?

Clinical trials are research studies designed to evaluate experimental treatments and procedures. Most breakthroughs in the diagnosis, treatment, and care of patients with cancer exist because of clinical trials.

Clinical trials have specific treatment plans with specific eligibility criteria. Criteria differ from study to study, and are frequently based on age, sex, type/stage of cancer, medical history, and current health status. Participation in a trial requires the ability to travel to the clinical trial center (in this case, the Saint John’s Cancer Institute).

Search for Open Clinical Trials at Saint John’s Cancer Institute.

What is it like to participate in a clinical trial?

Mark Perzley is interviewed by Saint John’s Cancer Institute in Santa Monica, California.

Saint John’s Experts Explain the Importance of Clinical Trials

Doctors, Kim Margolin, Santosh Kesari, Przemyslaw Twardowski, Parvin Peddi, Leland Foshag, and Emma Chacon deep dive into clinical trials and their significance to their patients and others.

Have questions?

For more information about any of our clinical trials, or general questions, please call our main hotline. See Clinical Trials FAQs for additional information.

Please call, 310-582-7448 to participate in a clinical trial

The clinical trials listed below represent active and enrolling trials. We implement, initiate, and oversee clinical trials here, at Saint John’s Cancer Institute, as well as other facilities in the Southern California region.

Search using key terms or filter by Centers of Excellence or by Lead Doctor.

Title	Center Name	Physician
Cognitive Training for Cancer Related Cognitive Impairment in Breast Cancer Survivors NCT ID : 05896189 Phase : N/A Location : Saint John's Cancer Institute	Breast Surgery and Oncology	Janie Grumley, M.D.
A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma NCT ID : 06246916 Phase : 3 Location : Saint John's Cancer Institute	Melanoma, Skin and Soft Tissue Tumors	Kim Margolin, M.D.
IMC-F106C Regimen Versus Nivolumab Regimens in Previously Untreated Advanced Melanoma (PRISM-MEL-301) (PRISM-MEL-301) NCT ID : 06112314 Phase : 2/3 Location : Saint John's Cancer Institute	Melanoma, Skin and Soft Tissue Tumors	Kim Margolin, M.D.
A Trial to Learn if Fianlimab and Cemiplimab Are Safe and Work Better Than Anti-PD1 Alone in Adult Participants With Resectable Stage 3 or 4 Melanoma NCT ID : 06190951 Phase : 2/3 Location : Saint John's Cancer Institute	Melanoma, Skin and Soft Tissue Tumors	Kim Margolin, M.D.
Long-Term Safety of Lutetium (177Lu) Vipivotide Tetraxetan in Participants With Prostate Cancer NCT ID : 05803941 Phase : 4 Location : Saint John's Cancer Institute	Urology and Urologic Oncology	Przemyslaw Twardowski, M.D.
Saruparib (AZD5305) vs Placebo in Men With Metastatic Castration-Sensitive Prostate Cancer Receiving Physician’s Choice New Hormonal Agents (EvoPAR-PR01) NCT ID : 06120491 Phase : 3 Location : Saint John's Cancer Institute	Urology and Urologic Oncology	Przemyslaw Twardowski, M.D.
Pembrolizumab and Pemetrexed for Progressive Chordoma NCT ID : NCT06794645 Phase : 2 Location : Saint John's Cancer Institute	Brain Tumors & Neuroscience	Naveed Wagle, M.D.
CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL) NCT ID : NCT03328078 Phase : 1/2 Location : Saint John's Cancer Institute	Brain Tumors & Neuroscience	Naveed Wagle, M.D.
A Study of NanO2™ Combined With Radiation and Temozolomide in Patients With Newly Diagnosed GBM (RESTORE) NCT ID : NCT03862430 Phase : 2 Location : Saint John's Cancer Institute	Brain Tumors & Neuroscience	Naveed Wagle, M.D.
A Randomized, Open-label, Phase 3 Study of MK-2870 in Combination With Pembrolizumab Compared to Pembrolizumab Monotherapy in the First-line Treatment of Participants With Metastatic Non-small Cell Lung Cancer With PD-L1 TPS Greater Than or Equal to 50% NCT ID : 06170788 Protocol Number : MK-2870-007 Phase : 3 Location : Disney Family Cancer Center	Thoracic	Karlton Wong, M.D.
A Phase 3 Study of Pembrolizumab in Combination With Carboplatin/Taxane (Paclitaxel or Nab-paclitaxel) Followed by Pembrolizumab With or Without Maintenance MK-2870 in the First-line Treatment of Metastatic Squamous Non-small Cell Lung Cancer NCT ID : 06422143 Protocol Number : MK-2870-023 Phase : 3 Location : Disney Family Cancer Center	Thoracic	Karlton Wong, M.D.
Study of the Bria-IMT Regimen and CPI vs Physicians’ Choice in Advanced Metastatic Breast Cancer (BRIA-ABC) NCT ID : 06072612 Phase : 3 Location : Saint John's Cancer Institute	Breast Surgery and Oncology	Parvin Peddi, M.D.
A Phase 1, Open-label Trial of Belzupacap Sarotalocan (AU-011) in Bladder Cancer NCT ID : 05483868 Phase : 1 Location : Saint John's Cancer Institute	Urology and Urologic Oncology	Jennifer Linehan, M.D.
A Beta-only IL-2 ImmunoTherapY Study (ABILITY-1) NCT ID : 05086692 Phase : 1/2 Location : Saint John's Cancer Institute	All Solid Tumors	Przemyslaw Twardowski, M.D.
Perioperative Pain Management Strategies in Oncoplastic Breast Surgery NCT ID : N/A Phase : N/A Location : Saint John's Cancer Institute	Breast Surgery and Oncology	Janie Grumley, M.D.
Copper Cu 64 PSMA I&T PET Imaging in Men With Suspected Recurrence of Prostate Cancer (Solar-Recur) NCT ID : 06235151 Phase : 3 Location : Saint John's Cancer Institute	Urology and Urologic Oncology	Przemyslaw Twardowski, M.D.
A Randomized Controlled Phase 2 Study of the Ketogenic Diet Versus Standard Dietary Guidance for Patients With Newly Diagnosed Glioblastoma in Combination With Standard-of-care Treatment NCT ID : 05708352 Protocol Number : IIT2022-06-HU-DIET2TREAT Phase : 2 Location : Santa Monica, CA	Brain Tumors & Neuroscience	Naveed Wagle, M.D.
A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer NCT ID : 05894239 Protocol Number : WO44263 Phase : 3 Location : Burbank, California	Breast Surgery and Oncology	Reva Basho, M.D.
Study of Chemotherapy Plus Ipatasertib for People With Solid Tumors With AKT Mutations, A ComboMATCH Treatment Trial NCT ID : 05554380 Protocol Number : EAY191-S3 Phase : 2 Location : Santa Monica, CA	Multiple Tumors	Reva Basho, M.D.
Testing the Use of Fulvestrant and Binimetinib Targeted Treatment for NF1 Mutation in Hormone Receptor-Positive Metastatic Breast Cancer (A ComboMATCH Treatment Trial) NCT ID : 05554354 Phase : 2 Location : Santa Monica, CA	Breast Surgery and Oncology	Reva Basho, M.D.
Testing the Role of FDG-PET/CT to Predict Response to Therapy Prior to Surgery for HER2-positive Breast Cancer, The DIRECT Trial NCT ID : 05710328 Protocol Number : EA1211 Phase : 2 Location : Santa Monica, Ca	Breast Surgery and Oncology	Parvin Peddi, M.D.
A Trial to See if the Combination of Fianlimab With Cemiplimab Works Better Than Pembrolizumab for Preventing or Delaying Melanoma From Coming Back After it Has Been Removed With Surgery NCT ID : 05608291 Protocol Number : R3767-ONC-2055 Phase : 3 Location : Saint John's Cancer Institute	Melanoma, Skin and Soft Tissue Tumors	Kim Margolin, M.D.
Study of REGN5678 (Anti-PSMAxCD28) With Cemiplimab (Anti-PD-1) in Patients With Metastatic Castration-resistant Prostate Cancer NCT ID : 03972657 Protocol Number : R5678-ONC-1879 Phase : 1/2 Location : Saint John's Cancer Institute	Urology and Urologic Oncology	Przemyslaw Twardowski, M.D.
Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab NCT ID : 05812807 Protocol Number : A012103 Phase : 3 Location : Saint John's Cancer Institute	Breast Surgery and Oncology	Parvin Peddi, M.D.
A Study to Test Different Doses of BI 1831169 Alone and in Combination With Ezabenlimab in People With Different Types of Advanced Cancer (Solid Tumors) NCT ID : 05155332 Protocol Number : 1456-0001 Phase : 1 Location : Saint John's Cancer Institute	All Solid Tumors	Naveed Wagle, M.D.
ONC201 in H3 K27M-mutant Diffuse Glioma Following Radiotherapy (the ACTION Study) (ACTION) NCT ID : 05580562 Protocol Number : ONC201-108 Phase : 3 Location : Saint John's Cancer Institute	Brain Tumors & Neuroscience	Naveed Wagle, M.D.
Biomarker Low Risk Node Positive Breast Cancer: TAILOR RT. NCT ID : 03488693 Protocol Number : CCTGMA.39 Phase : 3 Location : Santa Monica, CA	Breast Surgery and Oncology	Janie Grumley, M.D.
Intermediate-size Expanded Access to ONC201 for Patients with H3 K27M-mutant and/or Midline Gliomas NCT ID : 04617002 Protocol Number : ONC028 Phase : N/A Location : Santa Monica, CA	Brain Tumors & Neuroscience	Naveed Wagle, M.D.
Study of Safety and Pharmacokinetic Properties of Oral OKN-007 in Patients With Recurrent High-Grade Glioma NCT ID : 05561374 Protocol Number : OKN-007-OL Phase : 1 Location : Saint John's Cancer Institute	Brain Tumors & Neuroscience	Naveed Wagle, M.D.
DecisionDx-Melanoma Impact on Sentinel Lymph Node Biopsy Decisions and Clinical Outcomes (DECIDE) NCT ID : N/A Protocol Number : CBI_2019_SLNBprosp_001 Phase : N/A Location : Santa Monica, CA	Melanoma, Skin and Soft Tissue Tumors	Richard Essner, M.D.
Safety and Preliminary Effectiveness of BNT327, an Investigational Therapy for Breast Cancer, When Given in Combination With Chemotherapy NCT ID : 06449222 Phase : 2 Location : Santa Monica, CA	Breast Surgery and Oncology	Parvin Peddi, M.D.
Optimizing Endocrine Therapy Through Motivational Interviewing and Text Interventions NCT ID : 04379570 Protocol Number : A191901 Phase : 4 Location : Santa Monica, CA	Breast Surgery and Oncology	Janie Grumley, M.D.